New Osteoporosis Drug Approved for Postmenopausal Women in England

Abaloparatide, a daily injection, offers hope for thousands at high risk of fractures, enhancing bone density and quality of life.

The drug will be available on the NHS within three months, benefiting over 14,000 women.
Abaloparatide stimulates bone growth and is self-administered via a pre-filled pen.
It is an alternative for those who cannot tolerate or have not responded to other treatments.
Osteoporosis affects over three million people in the UK, with prevalence increasing with age.
Hormone replacement therapy remains a key treatment, but abaloparatide provides an additional option.